Team:Penn/Too Soon To Treat

From 2013.igem.org

(Difference between revisions)
 
(2 intermediate revisions not shown)
Line 25: Line 25:
  <div id="text">
  <div id="text">
<div class = "textwrap">
<div class = "textwrap">
-
<header><h1><b><center>The potential of epigenetic therapy and the need for elucidation of risks</center></b></h1></header>
+
<header><h1><b><center>The Potential of Epigenetic Therapy and the Need for Elucidation of Risks</center></b></h1></header>
<p>&nbsp;</p>
<p>&nbsp;</p>
<i>This article has been accepted for publication by "the nation's premiere peer-reviewed undergraduate bioethics journal", <a href="http://bioethicsjournal.com/index.html"> the Penn Bioethics Journal</a>. We're very appreciative of their support and excited to spread the word about iGEM and epigenetic engineering amongst their broad readership. </i><br/>
<i>This article has been accepted for publication by "the nation's premiere peer-reviewed undergraduate bioethics journal", <a href="http://bioethicsjournal.com/index.html"> the Penn Bioethics Journal</a>. We're very appreciative of their support and excited to spread the word about iGEM and epigenetic engineering amongst their broad readership. </i><br/>
<p>&nbsp;</p>
<p>&nbsp;</p>
-
<p><strong>Abstract</strong> <br />
 
-
Epigenetic phenomena are known to be a root cause of many common diseases. To date, the FDA has approved four epigenetic therapies that show promising results for prolonging lives of terminal cancer patients. However, there is a relative lack of knowledge about long-term epigenetic effects, especially those that affect future generations. We propose a heightening of standards for epigenetic therapy: therapies should be targeted to specific genes in specific cells, patients’ epigenomes should be sequenced before and after treatment, and germline effects should be unacceptable. Moreover, further research should be performed to answer questions about transgenerational epigenetic effects, to analyze the effects of altered epigenomes in the long term, and to develop superior assays for screening epigenomes.</p>
 
<p>&nbsp;</p>
<p>&nbsp;</p>
<a href="https://static.igem.org/mediawiki/2013/a/ae/Penn_iGEM_2013_PBJ_Article.pdf">Download the full article as a PDF.</a>
<a href="https://static.igem.org/mediawiki/2013/a/ae/Penn_iGEM_2013_PBJ_Article.pdf">Download the full article as a PDF.</a>
-
 
+
<p>&nbsp;</p>
 +
<p>&nbsp;</p>
 +
<embed src="https://static.igem.org/mediawiki/2013/a/ae/Penn_iGEM_2013_PBJ_Article.pdf" width='800' height='600'>
</div>
</div>

Latest revision as of 03:52, 29 October 2013

Penn iGEM

The Potential of Epigenetic Therapy and the Need for Elucidation of Risks

 

This article has been accepted for publication by "the nation's premiere peer-reviewed undergraduate bioethics journal", the Penn Bioethics Journal. We're very appreciative of their support and excited to spread the word about iGEM and epigenetic engineering amongst their broad readership.

 

 

Download the full article as a PDF.

 

 

Retrieved from "http://2013.igem.org/Team:Penn/Too_Soon_To_Treat"